AbbVie Inc. is 136.9x more valuable than Arcutis Biotherapeutics, Inc. by market capitalization ($399.47 B vs $2.92 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ARQT | ABBV |
|---|---|---|
| Market cap | $2.92 B | $399.47 B |
| US-listed rank | #1826 | #28 |
| Revenue (latest FY) | $376.07M | $61.16B |
| Net income (latest FY) | -$16.14M | $4.23B |
| Net margin | -4.3% | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 798 | 1,008 |
AbbVie Inc. is 136.9x more valuable than Arcutis Biotherapeutics, Inc. by market capitalization ($399.47 B vs $2.92 B).
In their latest fiscal years, Arcutis Biotherapeutics, Inc. reported $376.07M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Arcutis Biotherapeutics, Inc. and AbbVie Inc., or browse the full rankings.